Literature DB >> 11597909

Examining basal chloride transport using the nasal potential difference response in a murine model.

K G Brady1, T J Kelley, M L Drumm.   

Abstract

Epithelia of humans and mice with cystic fibrosis are unable to secrete chloride in response to a chloride gradient or to cAMP-elevating agents. Bioelectrical properties measured using the nasal transepithelial potential difference (TEPD) assay are believed to reflect these cystic fibrosis transmembrane conductance regulator (CFTR)-dependent chloride transport defects. Although the response to forskolin is CFTR mediated, the mechanisms responsible for the response to a chloride gradient are unknown. TEPD measurements performed on inbred mice were used to compare the responses to low chloride and forskolin in vivo. Both responses show little correlation between or within inbred strains of mice, suggesting they are mediated through partially distinct mechanisms. In addition, these responses were assayed in the presence of several chloride channel inhibitors, including DIDS, diphenylamine-2-carboxylate, glibenclamide, and 5-nitro-2-(3-phenylpropylamino)-benzoic acid, and a protein kinase A inhibitor, the Rp diastereomer of adenosine 3',5'-cyclic monophosphothioate (Rp-cAMPS). The responses to low chloride and forskolin demonstrate significantly different pharmacological profiles to both DIDS and Rp-cAMPS, indicating that channels in addition to CFTR contribute to the low chloride response.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11597909     DOI: 10.1152/ajplung.2001.281.5.L1173

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  6 in total

1.  Lubiprostone activates non-CFTR-dependent respiratory epithelial chloride secretion in cystic fibrosis mice.

Authors:  Kelvin D MacDonald; Karen R McKenzie; Mark J Henderson; Charles E Hawkins; Neeraj Vij; Pamela L Zeitlin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-09-19       Impact factor: 5.464

2.  Generation of a conditional null allele for Cftr in mice.

Authors:  Craig A Hodges; Calvin U Cotton; Mark R Palmert; Mitchell L Drumm
Journal:  Genesis       Date:  2008-10       Impact factor: 2.487

3.  Cystic fibrosis growth retardation is not correlated with loss of Cftr in the intestinal epithelium.

Authors:  Craig A Hodges; Brian R Grady; Kirtishri Mishra; Calvin U Cotton; Mitchell L Drumm
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-06-09       Impact factor: 4.052

4.  INO-4995 therapeutic efficacy is enhanced with repeat dosing in cystic fibrosis knockout mice and human epithelia.

Authors:  Alexis E Traynor-Kaplan; Mark Moody; Magda Nur; Sherif Gabriel; Philip W Majerus; Mitchell L Drumm; Beatrice Langton-Webster
Journal:  Am J Respir Cell Mol Biol       Date:  2009-04-03       Impact factor: 6.914

5.  A G542X cystic fibrosis mouse model for examining nonsense mutation directed therapies.

Authors:  Daniel R McHugh; Miarasa S Steele; Dana M Valerio; Alexander Miron; Rachel J Mann; David F LePage; Ronald A Conlon; Calvin U Cotton; Mitchell L Drumm; Craig A Hodges
Journal:  PLoS One       Date:  2018-06-20       Impact factor: 3.240

6.  Characterization of nasal potential difference in cftr knockout and F508del-CFTR mice.

Authors:  Emilie Lyne Saussereau; Delphine Roussel; Siradiou Diallo; Laurent Debarbieux; Aleksander Edelman; Isabelle Sermet-Gaudelus
Journal:  PLoS One       Date:  2013-03-07       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.